Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.45 – $0.55
0% from low
Exchange
OTC Link
ADRC
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $899.0M | $997.5M | $961.6M | $1.17B | $1.03B | $1.11B | $1.02B | $995.4M |
| Cost of revenue | $586.5M | $765.3M | $722.6M | $857.6M | $871.7M | $939.6M | $845.7M | $893.5M |
| Gross profit | $312.5M | $232.2M | $239.0M | $310.5M | $160.5M | $170.9M | $171.1M | $101.9M |
| Gross margin | 34.8% | 23.3% | 24.9% | 26.6% | 15.5% | 15.4% | 16.8% | 10.2% |
| R&D | $50.8M | $50.8M | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $93.0M | $29.5M | $51.8M | $117.7M | −$15.4M | −$5.5M | $23.2M | −$59.3M |
| EBITDA | $239.2M | $179.4M | $186.6M | $212.0M | $79.1M | $178.0M | $90.4M | $15.9M |
| Net income | $80.3M | $75.4M | $90.8M | $122.7M | $23.6M | $31.2M | $26.7M | −$67.9M |
| Net margin | 8.9% | 7.6% | 9.4% | 10.5% | 2.3% | 2.8% | 2.6% | -6.8% |
| EPS (diluted) | 0.49 | 0.46 | 0.56 | 0.76 | 0.14 | 0.19 | 0.16 | -0.42 |
Annual figures · source: Financial Modeling Prep
SHENGUAN HLDGS GP UNS/ADR
No one on the platform currently holds SHGXY.
No tracked institution reports a position in SHGXY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-06-11 | $0.0509 | 2025-07-24 |
| 2024-06-06 | $0.0511 | 2024-07-22 |
| 2024-06-06 | $0.0511 | 2024-07-22 |
No one on the platform has traded SHGXY yet.
| $88M |
| — |
| ESGHESG Inc. | $1.79 | +0.00% | $46M | — |
| GBCMYGlobal Bio-chem Technology Group Company Limited | $4.14 | +0.00% | $7M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.3× earnings vs its 4.8× historical median P/E.
Fair value ≈ $1.66 · price $0.45 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.